Global Roles and Duties of Ethics Committees in Clinical Research

Introduction to Ethics Committees and Their Global Significance

Ethics Committees—referred to as Institutional Review Boards (IRBs) in the United States and Independent Ethics Committees (IECs) in the European Union—are cornerstones of human subject protection in clinical trials. Their role is mandated under the ICH-GCP E6 guideline and reinforced by national regulations worldwide. These committees are charged with ensuring that research involving human participants is scientifically valid, ethically justified, and compliant with both regulatory and moral standards. As globalization increases the number of multinational studies, understanding the diverse roles of ethics committees across regions becomes essential for sponsors, investigators, and regulators.

Globally, ethics committees balance two imperatives: advancing medical innovation and safeguarding participant rights. This responsibility requires careful evaluation of study design, informed consent, risk mitigation, and ongoing monitoring. While the principles are universal, regional variations exist in scope, authority, and practice, making harmonization a continuing challenge.

Core Responsibilities of Ethics Committees

Ethics Committees carry out responsibilities that extend from the earliest planning stages of a clinical trial to its closeout. These duties include:

• Scientific and ethical review: Evaluating whether the study design is robust, ethical, and likely to achieve meaningful results.
• Informed consent approval: Assessing clarity, comprehensibility, and completeness of consent documents.
• Risk-benefit analysis: Weighing potential risks against anticipated benefits to participants and society.
• Participant protection: Ensuring vulnerable populations are not exploited and that adequate safeguards are in place.
• Ongoing monitoring: Reviewing protocol amendments, adverse event reports, and progress updates throughout the trial.
• Confidentiality assurance: Ensuring sensitive data is protected in line with regulations such as GDPR and HIPAA.

By fulfilling these roles, ethics committees act as independent guardians of participant safety, bridging the gap between investigators and regulators.

Variability in Global Ethics Committee Structures

The organization, mandate, and authority of ethics committees vary globally. For example:

• ➤ In the United States, IRBs are legally mandated under the Common Rule (45 CFR 46). They have broad oversight powers and are subject to FDA audits.
• ➤ In the European Union, IECs operate under the Clinical Trials Regulation (EU CTR 536/2014), with responsibilities coordinated with national competent authorities.
• ➤ In India, ethics committees must be registered with the Drugs Controller General of India (DCGI) and comply with local Schedule Y requirements, reinforced by ICMR guidelines.
• ➤ In Japan, Institutional Review Boards are regulated by the PMDA and must align with the Japanese registry system.
• ➤ In Africa and Latin America, capacity building is still ongoing, with WHO-supported regional training initiatives for ethics governance.

These differences highlight the challenge of conducting multinational trials, where sponsors must navigate a patchwork of requirements while maintaining consistent participant protection standards.

Case Study: Global Ethics in a Multinational Oncology Trial

Consider a Phase III oncology trial conducted across the United States, India, and Germany. Each country required ethics committee approval, but processes differed:

This example illustrates the varying timelines and documentation demands that sponsors must account for during planning.

Ongoing Oversight and Monitoring Responsibilities

Ethics Committees’ responsibilities do not end with initial approval. Continuous oversight is a fundamental ethical obligation:

• Review of protocol amendments: Any change in trial design must be reviewed and approved before implementation.
• Safety monitoring: Committees assess Serious Adverse Event (SAE) reports and may require protocol adjustments.
• Annual or periodic review: Long-term studies must be re-evaluated periodically to ensure ongoing compliance.
• Site monitoring visits: In some jurisdictions, committees may conduct site inspections to verify adherence to approved protocols.

Challenges and Future of Global Ethics Oversight

As clinical trials become increasingly globalized and complex, ethics committees face challenges in harmonizing practices. Differences in resources, training, and regulatory frameworks often affect the quality of ethical review. Emerging areas such as decentralized trials, genomic research, and AI-based interventions also demand updated guidance from ethics bodies.

Organizations like the WHO and the International Council for Harmonisation (ICH) are working toward capacity building and harmonization efforts. Digital tools for ethics review, shared registries, and standardized SOPs are anticipated to strengthen global oversight.

Conclusion: Strengthening Global Ethics Committees

Ethics Committees globally serve as the guardians of human research participants. While their core responsibilities remain universal—safeguarding rights, ensuring risk-benefit balance, and upholding scientific integrity—their operations vary widely. To keep pace with the globalization of research, harmonization, training, and regulatory convergence are essential. Strong ethics committees build trust in clinical research, ensuring that scientific progress does not come at the expense of participant dignity and safety.

Building a Robust and Effective Ethical Review Process in Clinical Research

Introduction: Why an Effective Ethical Review Matters

The ethical review process is the cornerstone of protecting human participants in clinical research. It ensures that trial protocols uphold scientific integrity while safeguarding the rights, safety, and dignity of participants. A robust ethical review not only complies with regulatory requirements (such as ICH-GCP and local laws) but also builds public trust and improves data credibility.

An effective review is not a one-time checkbox—it is a dynamic, multidisciplinary process requiring coordinated input from scientific, legal, and community perspectives. This article breaks down the essential components of an ethical review process that meets global standards while adapting to local needs.

1. Diverse and Qualified Ethics Committee Composition

A well-constituted ethics committee (EC)—also known as an Institutional Review Board (IRB)—is foundational. According to ICH-GCP E6(R2), the EC must be composed of both scientific and non-scientific members, including:

• At least one member from the medical or clinical field
• At least one non-scientific member (e.g., social worker, community representative)
• A legal or ethical expert
• A chairperson who is independent of the trial site

Diversity ensures balanced viewpoints, especially when evaluating protocols involving vulnerable populations (children, pregnant women, terminally ill, etc.). For example, in a pediatric oncology trial, having a pediatrician and a parent representative can help ensure that unique ethical issues are fully addressed.

2. Clearly Defined SOPs for Review and Decision-Making

Standard Operating Procedures (SOPs) are critical for consistency and accountability in ethical review. SOPs should define:

• How protocols are submitted and reviewed
• Meeting frequency and quorum requirements
• Criteria for approval, conditional approval, or rejection
• Documentation and communication of decisions
• Review of amendments and safety reports

For example, the CDSCO in India mandates that registered ECs maintain SOPs covering member responsibilities, conflict of interest policies, and timelines for decisions. In the EU, under the Clinical Trials Regulation (CTR 536/2014), coordinated ethics reviews require harmonized SOPs across member states.

3. Comprehensive Protocol Review Criteria

Effective ethical review goes beyond ticking regulatory boxes. The committee must conduct a multi-angle assessment that includes:

• Scientific validity: Is the study methodologically sound enough to justify exposing humans to potential risk?
• Risk-benefit analysis: Are the risks minimized and outweighed by potential benefit?
• Informed consent quality: Is the language understandable and honest?
• Privacy and confidentiality: Are data protection measures in place?
• Subject selection: Are inclusion/exclusion criteria just and fair?

For example, in a placebo-controlled trial for a life-saving treatment, the EC must assess whether the placebo use is ethically defensible when an active comparator may be more appropriate.

4. Informed Consent Document Evaluation

Ethics committees are responsible for ensuring the informed consent form (ICF) is clear, comprehensive, and culturally appropriate. Key elements include:

• Plain-language explanation of study purpose, risks, and procedures
• Participant’s right to withdraw anytime
• Confidentiality of data and biological samples
• Compensation in case of trial-related injury

Many regions require ICFs to be translated into local languages. In Japan and the EU, ECs may require back-translations to verify accuracy. For best practices, review sample templates provided by ISRCTN.

5. Review of Protocol Amendments and Re-Consent

Ethical oversight does not end at protocol approval. Any substantial change to the trial must be reviewed again by the EC. This includes:

• Changes in dosage, administration, or study population
• New risk information or updated SAE trends
• Revised ICFs requiring subject re-consent

For instance, during a COVID-19 trial, mid-study findings about cardiac side effects prompted a protocol amendment and re-consent requirement. A responsive EC will convene quickly to evaluate such changes and prevent enrollment delays.

6. Ongoing Safety and Monitoring Review

Effective ECs engage in continuous monitoring. This includes:

• Review of serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs)
• Periodic safety update reports (PSURs)
• Annual progress reports and DSMB recommendations

In countries like Canada and Australia, ECs can suspend or withdraw approval based on safety findings, ensuring participant protection even after recruitment ends.

7. Documentation and Archiving of Ethics Committee Decisions

Proper documentation enables traceability, transparency, and regulatory inspection readiness. ECs should maintain:

• Minutes of meetings with detailed deliberations
• Attendance records and member votes
• Correspondence with investigators and sponsors
• Version-controlled documents of ICFs, protocols, and amendments

GCP-compliant archiving of EC records for 3–5 years is essential in jurisdictions such as the US (FDA 21 CFR Part 56) and the EU. During EMA audits, EC document completeness is often a key inspection focus.

8. EC Training and Capacity Building

Committee members must be trained in bioethics, GCP guidelines, regional regulations, and trial methodologies. Many regulatory bodies now mandate initial and refresher trainings. Examples include:

• CDSCO, India: Requires annual training logs and SOPs covering capacity development
• NIH-funded US sites: Mandate HSP/GCP certifications for EC members

Capacity building helps avoid superficial reviews and ensures that members can critically engage with complex trial designs, emerging technologies (e.g., gene therapy), and adaptive protocols.

Conclusion: Strengthening Ethics Review for Responsible Research

A truly effective ethical review process is more than compliance—it is a moral imperative. By focusing on structured procedures, member training, clear communication, and post-approval monitoring, ethics committees can ensure trials are not only scientifically sound but also ethically robust.

With increasing globalization of trials, ECs must stay agile, tech-enabled, and globally harmonized—ensuring that the protection of trial participants remains at the heart of clinical research conduct.